<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>273-POTASSIUM-LOWERING-MEDICATIONS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="POTASSIUM LOWERING AGENTS" code="C03-001" /></DRUG1>
<DRUG2>
<CLASS name="OTHER POTASSIUM LOWERING AGENTS" code="C03-001" /></DRUG2>
<DESCRIPTION>Increased risk of hypokalemia</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Monitoring of kalemia with correction if needed.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>273-POTASSIUM-LOWERING-MEDICATIONS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="POTASSIUM LOWERING AGENTS" code="C03-001" /></DRUG1>
<DRUG2>
<DRUG name="DIGOXIN " rxcui="3407">
<ATC code="C01AA05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Hypokaliemia that promotes the toxic effects of the digitalics.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Correct beforehand any hypokaliemia; maintain clinical monitoring, electrolite monitoring, and EKG.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>273-POTASSIUM-LOWERING-MEDICATIONS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="POTASSIUM LOWERING AGENTS" code="C03-001" /></DRUG1>
<DRUG2>
<CLASS name="SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES" code="C01-N05" /></DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially torsades de pointes</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Correct any hypokalemia before administering the product and maintain clinical monitoring, electrolyte monitoring and electrocardiographic monitoring. </COMMENT>
</INTERACTION>
</INTERACTIONS>
